📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: CinRx

1.1 - Company Overview

CinRx Logo

CinRx

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of therapies for unmet needs, advancing new molecular entities via partnerships and expertise. Pipeline includes obesity treatments such as CIN-110 (PYY3-36 analog), CIN-109 (GDF-15 analog), and CIN-209 (GLP-1/GDF-15 dual agonist); TTP399, an oral glucokinase activator adjunct to insulin for type 1 diabetes; CIN-102, a D2/D3 antagonist for gastroparesis; CIN-103, phloroglucinol for IBS-D.

Products and services

  • CIN-209: A dual-agonist combining GLP-1 and GDF-15 to deliver enhanced weight loss specifically targeted to obesity treatment
  • TTP399: An oral small-molecule glucokinase activator developed for adjunctive use with insulin in type 1 diabetes to reduce hypoglycemic events during routine treatment regimens
  • CIN-110: A peptide-based PYY3-36 analog engineered to reduce appetite and aid weight loss specifically for obesity treatment

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to CinRx

VectivBio Logo

VectivBio

HQ: Switzerland Website
  • Description: Provider of clinical-stage biotechnology solutions developing transformational medicines for serious rare diseases. Offerings include LINZESS (linaclotide) for IBS-C and CIC; apraglutide, an investigational once-weekly GLP-2 analog for SBS-IF; CNP-104, a potential treatment for primary biliary cholangitis; and IW-3300, a GC-C agonist in development for visceral pain conditions including IC/BPS and endometriosis.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full VectivBio company profile →
NuvoMed Logo

NuvoMed

HQ: United States Website
  • Description: Provider of a patented, disposable medical device (DisImpactor) for safe, fast, and effective relief of fecal impaction, delivering maximum comfort and clinical efficacy. Committed to improving this unpleasant procedure for patients and physicians and to technologies that enhance patient outcomes and healthcare delivery.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full NuvoMed company profile →
Inventiva Logo

Inventiva

HQ: France Website
  • Description: Provider of oral small molecule therapies in development for fibrosis, lysosomal storage disorders and oncology. Pipeline includes lanifibranor (Phase III for NASH) and odiparcil (Phase IIa for MPS VI), the PanNASH research initiative, partnerships with Sino Biopharm and Hepalys Pharma, and a 240,000-compound library supporting discovery.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Inventiva company profile →
Neurogastrx Logo

Neurogastrx

HQ: United States Website
  • Description: Provider of biopharmaceutical drug development, focusing on NG101, an oral small molecule dopamine D2 receptor antagonist for the treatment of gastroparesis, which has completed a Phase 2 clinical trial.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Neurogastrx company profile →
CapsoVision Logo

CapsoVision

HQ: United States Website
  • Description: Provider of capsule endoscopy solutions and healthcare-focused medical devices, from a global innovator specializing in capsule endoscopy, medical device, and healthcare.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full CapsoVision company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for CinRx

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to CinRx

2.2 - Growth funds investing in similar companies to CinRx

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for CinRx

4.2 - Public trading comparable groups for CinRx

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to CinRx

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About CinRx

What does CinRx do?

CinRx is a provider of therapies for unmet needs, advancing new molecular entities via partnerships and expertise. Pipeline includes obesity treatments such as CIN-110 (PYY3-36 analog), CIN-109 (GDF-15 analog), and CIN-209 (GLP-1/GDF-15 dual agonist); TTP399, an oral glucokinase activator adjunct to insulin for type 1 diabetes; CIN-102, a D2/D3 antagonist for gastroparesis; CIN-103, phloroglucinol for IBS-D.

Who are CinRx's competitors?

CinRx's competitors and similar companies include VectivBio, NuvoMed, Inventiva, Neurogastrx, and CapsoVision.

Where is CinRx headquartered?

CinRx is headquartered in United States.

How many employees does CinRx have?

CinRx has 1,000 employees 🔒.

When was CinRx founded?

CinRx was founded in 2010 🔒.

What sector and industry vertical is CinRx in?

CinRx is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for CinRx

Who are the top strategic acquirers in CinRx's sector and industry

Top strategic M&A buyers and acquirers in CinRx's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for CinRx?

Top strategic M&A buyers groups and sectors for CinRx include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in CinRx's sector and industry vertical

Which are the top PE firms investing in CinRx's sector and industry vertical?

Top PE firms investing in CinRx's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in CinRx's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in CinRx's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in CinRx's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to CinRx include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in CinRx's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for CinRx?

The key public trading comparables and valuation benchmarks for CinRx include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for CinRx for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for CinRx with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in CinRx's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for CinRx with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in CinRx's' sector and industry vertical?

Access recent funding rounds and capital raises in CinRx's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for CinRx